CELL INTELLIGENCE · 肿瘤细胞治疗研究

为体弱和老年骨髓瘤患者定制治疗

Tailoring Therapy for Frail and Elderly Myeloma Patients.

Arlocabtagene Autoleucel（GPRC5D CAR-T）治疗多发性骨髓瘤：II 期临床试验

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

这是一项 II 期注册临床试验，评估细胞治疗用于多发性骨髓瘤的疗效与安全性。研究设计：2 个分组。当前状态：招募中。计划入组 230 例。试验地点：美国 · 伯明翰、吉尔伯特、小石城、洛杉矶（共 52 个中心）。登记号：NCT06297226。

Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

靶向 GPRC5D 的双特异性和三特异性抗体在多发性骨髓瘤中的应用：当前证据与新兴策略

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

重新定义复发/难治性多发性骨髓瘤的二线治疗策略、序贯治疗及真实世界实施：来自第 31 届欧洲血液学协会年会的见解

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st A

多发性骨髓瘤 CAR-T 细胞治疗的全球趋势：2013-2025 年文献计量学分析

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.

靶向 BCMA、GPRC5D 或 FcRH5 的 T 细胞衔接器治疗复发/难治性多发性骨髓瘤：CAR-T 细胞疗法之外的格局——系统综述与网络 Meta 分析

T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review

革新 2L+骨髓瘤：关于 BCMA 靶向双特异性抗体治疗新时代的播客

Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies.

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

BCMA 与 GPRC5D 嵌合抗原受体（CAR）T 细胞同时输注治疗晚期多发性骨髓瘤

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.